Successful Treatment of Histiocytic Sarcoma in Childhood
Haroula Tsipou, Georgia Avgerinou, Stavros Glentis, Kalliopi Stefanaki, Antonis Kattamis

TL;DR
A three-year-old girl with histiocytic sarcoma in her calf was successfully treated using a chemotherapy protocol designed for Langerhans Cell Histiocytosis.
Contribution
This case demonstrates the successful use of the LCH-IV protocol for treating histiocytic sarcoma in a pediatric patient.
Findings
Histiocytic sarcoma is rare in children and typically affects adults.
The LCH-IV chemotherapy protocol was effective in treating the pediatric HS case.
Histopathological and cellular origin verification is essential for HS diagnosis.
Abstract
Histiocytic sarcoma (HS) is a rare malignant neoplasm that belongs to malignant histiocytoses. HS primarily occurs in adult males and is exceptionally uncommon in pediatric populations. Extranodal regions represent the most common sites of HS manifestation. Diagnosis necessitates histopathological evidence of neoplasm, along with verification of cellular origin through specialized studies. Here, we describe a case of a three-year-old female toddler with HS in her calf that was successfully treated with the chemotherapy protocol of Langerhans Cell Histiocytosis (LCH)-IV, the International Collaborative Treatment Protocol for Children and Adolescents with LCH, version 1.3.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHistiocytic Disorders and Treatments · Genetic and rare skin diseases. · Tuberous Sclerosis Complex Research
